Michael Kunicki

Stanford University — United States

Medicine · Health Sciences

8h-index1.2kcitations23works28.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(21), Glioma Diagnosis and Treatment(7), Immunotherapy and Immune Responses(5), Acute Lymphoblastic Leukemia research(4), Immune Cell Function and Interaction(2)

Publications23 total

269 Humanized anti-CAR antibodies affect durable response to GD2-CAR T-cells in diffuse midline glioma
Regular and Young Investigator Award Abstracts·2025Open Access
Author Correction: Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas
Nature·2024· 12 citedOpen Access
Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas
Nature·2024· 126 citedOpen Access
Sequential intravenous and intracerebroventricular GD2-CAR T-cell therapy for H3K27M-mutated diffuse midline gliomas
2024· 6 citedOpen Access
DIPG-47. SEQUENTIAL INTRAVENOUS AND INTRACEREBROVENTRICULAR GD2-CAR T-CELL THERAPY FOR H3K27M-MUTATED DIFFUSE MIDLINE GLIOMAS
Neuro-Oncology·2024Open Access
Abstract 959: Immune signatures of GD2 CAR T cell activity in H3K27M+ diffuse midline glioma patients
Cancer Research·2023· 3 cited
Long-Term Follow-up of CD19/22 CAR Therapy in Children and Young Adults with B-ALL Reveals Efficacy, Tolerability and High Survival Rates When Coupled with Hematopoietic Stem Cell Transplantation
Blood·2022· 4 cited
Standard Cytogenetic Risk Stratification Is Not Predictive of CD19 CAR Outcomes and Impact of Disease Burden Varies between Cytogenetic Risk Groups
Blood·2022· 2 cited
Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia
Journal of Clinical Oncology·2022· 71 citedOpen Access
Abstract CT001: Major tumor regressions in H3K27M-mutated diffuse midline glioma (DMG) following sequential intravenous (IV) and intracerebroventricular (ICV) delivery of GD2-CAR T cells
Cancer Research·2022· 7 cited
DIPG-15. Major tumor regressions in H3K27M-mutated diffuse midline glioma (DMG) following sequential intravenous (IV) and intracerebroventricular (ICV) delivery of GD2-CAR T-cells
Neuro-Oncology·2022· 2 citedOpen Access
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
Nature·2022· 740 citedOpen Access
Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report
Blood Advances·2021· 76 citedOpen Access
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy
Blood Advances·2021· 103 citedOpen Access
Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia
Blood·2021· 11 citedOpen Access
Abstract CT031: GD2 CAR T cells mediate clinical activity and manageable toxicity in children and young adults with DIPG and H3K27M-mutated diffuse midline gliomas
Cancer Research·2021· 8 cited
OMIC-11. SINGLE CELL RNA SEQUENCING FROM THE CSF OF SUBJECTS WITH H3K27M+ DIPG/DMG TREATED WITH GD2 CAR T-CELLULAR THERAPY
Neuro-Oncology·2021· 3 citedOpen Access
EPCT-14. GD2 CAR T-CELLS MEDIATE CLINICAL ACTIVITY AND MANAGEABLE TOXICITY IN CHILDREN AND YOUNG ADULTS WITH H3K27M-MUTATED DIPG AND SPINAL CORD DMG
Neuro-Oncology·2021· 6 citedOpen Access
Fludarabine-exposure predicts disease control following CD19-specific car t cell (tisagenlecleucel); a report from pediatric real-world car consortium
Cytotherapy·2021· 1 cited
Predictive Value of Next-Generation Sequencing (NGS) Following Tisagenlecleucel in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia
Transplantation and Cellular Therapy·2021· 2 cited
page 1 of 2Next →

Frequent Co-authors

Liora M. Schultz(23), Christina Baggott(21), Sharon Mavroukakis(16), Emily Egeler(16), Snehit Prabhu(16), Sneha Ramakrishna(14), Kara L. Davis(14), Crystal L. Mackall(14), Robbie G. Majzner(13), Rebecca M. Richards(13), Valentin Barsan(13), Jennifer Moon(13), Bita Sahaf(13), Jasia Mahdi(12), Michelle Fujimoto(12), Cynthia Campen(12), Steven A. Feldman(12), Michelle Monje(12), Shabnum Patel(11), Harshini Chinnasamy(11)